What is Stella?
Stella is at the forefront of developing innovative therapeutic solutions for mental trauma. The company's core offering centers on a modified Stellate Ganglion Block (SGB) procedure, designed to modulate the body's fight or flight response. This treatment is pioneered by Dr. Eugene Lipov, a distinguished board-certified anesthesiologist with over fifteen years of experience and more than 1,000 SGB procedures performed globally for mental trauma-related symptoms. Stella's approach targets the physiological underpinnings of trauma, aiming to provide relief to millions affected by its debilitating effects.
How much funding has Stella raised?
Stella has raised a total of $7M across 1 funding round:
Private Equity
$7M
Private Equity (2023): $7M, investors not publicly disclosed
What's next for Stella?
With the recent major enterprise-level funding and strategic investment, Stella is poised for significant expansion and further development of its groundbreaking SGB therapy. This capital injection is expected to accelerate research initiatives, enhance clinical trial capabilities, and potentially broaden the accessibility of their treatment. The company's focus on a scientifically validated, minimally invasive procedure positions it for substantial growth within the mental health and wellness market, aiming to establish SGB as a leading intervention for trauma-related conditions.
See full Stella company page
